These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15094600)

  • 21. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R; Lipponen P; Syrjänen K
    Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.
    Bacus SS; Ruby SG
    Pathol Annu; 1993; 28 Pt 1():179-204. PubMed ID: 8093211
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prognostic factors in breast cancer patients].
    Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
    Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
    [No Abstract]   [Full Text] [Related]  

  • 25. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
    Fischer-Colbrie J; Witt A; Heinzl H; Speiser P; Czerwenka K; Sevelda P; Zeillinger R
    Anticancer Res; 1997; 17(1B):613-9. PubMed ID: 9066588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
    Ayad E; Francis I; Peston D; Shousha S
    Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prognostic factors in breast cancer].
    Jonat W; Eidtmann H; Friedrichs K
    Gynakologe; 1994 Feb; 27(1):37-44. PubMed ID: 8168736
    [No Abstract]   [Full Text] [Related]  

  • 28. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer.
    Morcos B; Jaradat I; El-Ghanem M
    Eur J Surg Oncol; 2011 May; 37(5):418-21. PubMed ID: 21316187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prediction of therapeutic response in breast carcinoma: predictive factors].
    Nesković-Konstantinović Z
    Srp Arh Celok Lek; 1999; 127(3-4):131-6. PubMed ID: 10500437
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antibodies in the immunohistochemical detection of estrogen and progesterone receptor status in breast carcinoma].
    Shui R; Yang W
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):229-31. PubMed ID: 25975902
    [No Abstract]   [Full Text] [Related]  

  • 35. [Guideline for testing of estrogen and progesterone receptors in breast cancer].
    Guideline Recommendations for Immunohistochemistry Detection in Breast Cancer Group
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):237-9. PubMed ID: 25975904
    [No Abstract]   [Full Text] [Related]  

  • 36. [Epidermal growth factor receptors and their ligands in endometrial carcinoma: correlation with clinico-morphologic factors and steroid receptors].
    Gershtein ES; Bocharova LB; Ermilova VD; Laktionov KP; Kushlinskiĭ
    Vopr Onkol; 2000; 46(2):180-6. PubMed ID: 10853417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [About a prevalent cervical node metastasis].
    Taix S; De Biasi C; Gal M; Coulibaly B
    Ann Pathol; 2013 Oct; 33(5):364-8. PubMed ID: 24238254
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytosolic estrogen and progesterone receptors in exocrine pancreatic adenocarcinoma.
    Mao C; Desaty D; Howard JM
    Int J Pancreatol; 1994 Apr; 15(2):155-6. PubMed ID: 8071573
    [No Abstract]   [Full Text] [Related]  

  • 39. Biological staging of incipient, in situ, and invasive breast carcinomas.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Nenci I
    Ann N Y Acad Sci; 1996 Apr; 784():381-94. PubMed ID: 8651586
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic significance of MUC1 epithelial mucin expression in breast cancer.
    McGuckin MA; Walsh MD; Hohn BG; Ward BG; Wright RG
    Hum Pathol; 1995 Apr; 26(4):432-9. PubMed ID: 7705823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.